Tenth Record-Breaking Year in a Row for ZEISS

Stuttgart, Germany (ots/PRNewswire) - Revenue increases by 11 percent to 6.4
billion euros - EBIT exceeds 1 billion euros for the first time

- All four segments contributed to growth
- Medical technology and industrial and research solutions ensure
above-average growth for the ZEISS Group
- Semiconductor Manufacturing Technology sees strong growth with new
EUV technology
- ZEISS CEO Michael Kaschke: "As a global technology leader, ZEISS is
on its way to becoming a shaper in its markets."

The ZEISS Group continued its growth trajectory, with revenue and earnings
reaching new heights in fiscal year 2018/19, which ended 30 September 2019.
Revenue grew by 11 percent, reaching 6.428 billion euros (previous year: 5.817
billion euros). Adjusted for currency and acquisition effects (like-for-like),
revenue rose by 8 percent. At 1.063 billion euros, earnings before interest and
taxes (EBIT) were significantly higher than the previous year (772 million
euros). The EBIT margin was 17 percent. Incoming orders increased by 9 percent,
reaching 6.575 billion euros for the first time.

"All ZEISS segments have developed extremely well. This is quite remarkable,
especially in the midst of an uncertain economic climate and profound structural
change in different industries," says President & CEO, Prof. Dr. Michael
Kaschke. "ZEISS has consistently prepared for these scenarios and is
well-positioned for the future as well as resilient thanks to its corporate
strategy, the ZEISS Agenda 2020. Moreover, as a global technology leader, ZEISS
is on its way in many segments and areas to becoming a shaper in its markets."

More information at www.zeiss.com/pressconference.

About ZEISS

ZEISS is an internationally leading technology enterprise operating in the
fields of optics and optoelectronics. In the previous fiscal year, the ZEISS
Group generated annual revenue totaling more than 6.4 billion euros in its four
segments Semiconductor Manufacturing Technology, Industrial Quality & Research,
Medical Technology and Consumer Markets (status: 30 September 2019).

For its customers, ZEISS develops, produces and distributes highly innovative
solutions for industrial metrology and quality assurance, microscopy solutions
for the life sciences and materials research, and medical technology solutions
for diagnostics and treatment in ophthalmology and microsurgery. The name ZEISS
is also synonymous with the world's leading lithography optics, which are used
by the chip industry to manufacture semiconductor components. There is global
demand for trendsetting ZEISS brand products such as eyeglass lenses, camera
lenses and binoculars.

With a portfolio aligned with future growth areas like digitalization,
healthcare and Smart Production and a strong brand, ZEISS is shaping the future
of technology and constantly advancing the world of optics and related fields
with its solutions. The company's significant, sustainable investments in
research and development lay the foundation for the success and continued
expansion of ZEISS' technology and market leadership.

With over 31,000 employees, ZEISS is active globally in almost 50 countries with
around 60 sales and service companies, 30 production sites and 25 development
sites. Founded in 1846 in Jena, the company is headquartered in Oberkochen,
Germany. The Carl Zeiss Foundation, one of the largest foundations in Germany
committed to the promotion of science, is the sole owner of the holding company,
Carl Zeiss AG

Further Information: www.zeiss.com

Press Contact Jörg Nitschke, Group SpokesmanPhone: +49 7364
20-3242E-Mail:
joerg.nitschke@zeiss.com

www.zeiss.com/newsroom

Additional content: https://www.presseportal.de/pm/69120/4465508
OTS: Carl Zeiss AG

Original-Content von: Carl Zeiss AG, übermittelt durch news aktuell